Fondazione CNAO – National Center of Oncological HadrontherapyADDRESS
Strada Campeggi 53, 27100 Pavia (PV) - ItalyFOUNDED
Oncological Hadrontherapy Center
The National Centre for Oncological Hadrontherapy (CNAO) of Pavia is an innovative and technologically advanced non-profit Foundation established in 2001 by the Italian Health Minister for the construction and management of an hadrontherapy center for the treatment of radio-resistant or inoperable tumors making use of carbon ions and protons.
For the first time a machine has been built in Italy whose features are specifically suited to treat cancer rather than to perform physics experiments. The treatment of tumors with hadrontherapy requires a particle accelerator, the synchrotron, apt to accelerate carbon ions and protons at a speed close to that of light, so as to acquire the energy necessary for the treatment of the tumor. The synchrotron of CNAO has obtained by the Istituto Superiore di Sanità the CE mark as medical device.
Hadrontherapy at CNAO is dispensed within the National Health Service for the pathologies included in the Essential Assistance Levels. Others pathologies can be treated in private pay regime according to CNAO therapeutic protocols.
Treatments have proved to be reliable, sure and effective.
Highly qualified and professional staff work in synergy to provide patients with the best curing perspectives.
Hadrontherapy is an advanced form of radiotherapy taking advantage of carbon ions or protons, other than the “conventional” one, using X rays.
Carbon ions cause 3 times greater damage to DNA than the one provoked by conventional radiotherapy and spare healthy surrounding tissues.
On the basis of defined and shared clinical protocols patients are pre‐selected and referred to CNAO for the treatments, maintaining the link with their referring healthcare structures.
Pathologies treated at CNAO and recognized by the Italian Health System:
– ORBITARY AND PERIORBITAL TUMORS, INCLUDING OCULAR MELANOMA
– ENCEPHALIC TRUNK AND SPINAL CORD TUMORS
– INTRACRANICAL MENINGIOMAS IN CRITICAL LOCATIONS
– ADENOID-CYSTIC CARCINOMAS OF SALIVARY GLANDS
– SKULL BASE AND SPINAL CHORDOMAS AND CHONDROSARCOMAS
– PEDIATRIC SOLID TUMORS
– TUMORS IN PATIENTS WITH GENETIC SYNDROMES
– SARCOMAS, INCLUDED OSTEOSARCOMA AND CHONDROSARCOMAS
– RETREATMENTS OF PATIENTS ALREADY TREATED WITH RADIOTHERAPY
In order to verify the indication for hadrontherapy treatment, it is necessary a preliminary medical evaluation. If, due to its characteristics, the case is considered treatable, the patient will be contacted within one week to arrange his first appointment at CNAO.
On CNAO website are indicated the modalities to send the clinical documentations.
Fondazione CNAO mission is not only care, but also research for oncological patients relief: clinical, radiobiological, medical physics and bioengineering research.
The clinical research includes novel and comparative studies on the use of hadrons with the aim of improving the application of hadrontherapy to new pathologies, in collaboration with national and international oncological centers.
The radiobiology research focused on the mechanism of radio-resistance, of interactions between hadrons and medicaments and of response of the healthy tissues.
The medical physics research based on analysis to improve the procedures of the particle beam quality control and develop more and more precise and performant tools to attack tumors.
The bioengineering research with the aim to develop of novel devices concerning patient’s positioning and the treatment of tumors located in moving organs.
CNAO is committed in national and international collaborations in clinical and research field.